Zymeworks Inc
NASDAQ:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NASDAQ:ZYME
Watchlist
Price: 12.45 USD -1.19% Market Closed
Market Cap: 867.5m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

ZYME Price Targets Summary
Zymeworks Inc

Wall Street analysts forecast ZYME stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ZYME is 22.84 USD with a low forecast of 13.13 USD and a high forecast of 31.5 USD.

ZYME Lowest Forecast
Wall Street Target
13.13 USD
5% Upside
ZYME Average Forecast
Wall Street Target
22.84 USD
83% Upside
ZYME Highest Forecast
Wall Street Target
31.5 USD
153% Upside
Lowest
Price Target
13.13 USD
5% Upside
Average
Price Target
22.84 USD
83% Upside
Highest
Price Target
31.5 USD
153% Upside
Zymeworks Inc Competitors:
Price Targets
MDGL
Madrigal Pharmaceuticals Inc
54% Upside
MRUS
Merus NV
66% Upside
ADCT
ADC Therapeutics SA
136% Upside
BSLN
Basilea Pharmaceutica AG
78% Upside
MDGL
Madrigal Pharmaceuticals Inc
54% Upside
MRUS
Merus NV
66% Upside
ADCT
ADC Therapeutics SA
136% Upside
BSLN
Basilea Pharmaceutica AG
78% Upside
PRLD
Prelude Therapeutics Inc
224% Upside
301047
Sino Biological Inc
23% Upside
PBYI
Puma Biotechnology Inc
23% Upside
ONCO
Oncopeptides AB
282% Upside

Revenue
Forecast

Revenue Estimate
Zymeworks Inc

For the last 9 years the compound annual growth rate for Zymeworks Inc's revenue is 26%. The projected CAGR for the next 3 years is 21%.

26%
Past Growth
21%
Estimated Growth
Estimates Accuracy
5%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Zymeworks Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-10%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Zymeworks Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-32%
Average Miss
What are analyst estimates?

See Also

Summary
ZYME intrinsic value, competitors valuation, and company profile.
DCF Valuation
ZYME stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ZYME stock valuation using valuation multiples.
Wall Street Estimates
ZYME price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ZYME stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is ZYME's stock price target?
Price Target
22.84 USD

According to Wall Street analysts, the average 1-year price target for ZYME is 22.84 USD with a low forecast of 13.13 USD and a high forecast of 31.5 USD.

What is Zymeworks Inc's Revenue forecast?
Projected CAGR
21%

For the last 9 years the compound annual growth rate for Zymeworks Inc's revenue is 26%. The projected CAGR for the next 3 years is 21%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 260,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.